多替诺雷在高尿酸血症与痛风治疗中的研究进展
Research progress on dotinurad in the treatment of hyperuricemia and gout
高尿酸血症作为嘌呤代谢紊乱引发的代谢异常综合征,患病率呈显著上升趋势,已成为重要的公共卫生问题。目前常用降尿酸药物因安全性局限亟须新治疗选择。多替诺雷作为新一代选择性尿酸重吸收抑制剂,通过精准靶向肾近端小管顶膜尿酸转运体 1(URAT1)发挥治疗作用,其作用机制为选择性抑制 URAT1 介导的尿酸 Cl−/有机阴离子交换重吸收通路,促进尿酸排泄,有助于维持长效稳态血药浓度。其主要经葡萄糖醛酸化/硫酸化代谢,轻中度肝肾功能不全者无需调整剂量,年龄性别差异无临床意义,且药物相互作用风险低。本文对多替诺雷的作用机制、药理研究、临床有效性和安全性等进行综述,为高尿酸血症伴痛风的治疗提供更多思路和选择。
Hyperuricemia, a metabolic disorder syndrome caused by dysregulation of purine metabolism, exhibits a significantly rising prevalence rate in China and has become a major public health concern. Currently available urate-lowering drugs face limitations in safety profiles, necessitating novel therapeutic options. Dotinurad, as a new-generation selective inhibitor of uric acid reabsorption, exerts its therapeutic effect by precisely targeting the urate transporter 1 (URAT1) on the apical membrane of renal proximal tubules. Its molecular mechanism involves the selective inhibition of the URAT1-mediated uric acid Cl-/organic anion exchange reabsorption pathway, thereby promoting uric acid excretion. This agent possesses pharmacokinetic characteristics including low volume of distribution and high plasma protein binding, ensuring long-lasting stable blood concentrations. It is primarily metabolized via glucuronidation/sulfation conjugation. Dosage adjustment is not required for patients with mild-to-moderate hepatic or renal impairment. Age and sex differences do not significantly affect its pharmacokinetics, and it carries a low risk of drug-drug interactions. This article reviews the fundamental profile, pharmacological research, clinical efficacy, and safety of dotinurad, aiming to provide expanded perspectives and alternatives for managing hyperuricemia with gout.
| [1] |
中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南 (2019)[J].中华内分泌代谢杂志, 2020, 36(1): 1-13. |
| [2] |
|
| [3] |
|
| [4] |
程伟刚, 李浩林, 杨娟娟, |
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
吴芃, 王亮, 李海涛, |
| [10] |
Japanese Society of Gout and Nucleic Acid Metabolism. Guideline for the management of hyperuricemia and gout[M]. 3rd ed. Tokyo: Japanese Society of Gout and Nucleic Acid Metabolism,2019. |
| [11] |
|
| [12] |
Nakatani H, Fushimi M, Sasaki T, |
| [13] |
|
| [14] |
Yanai H, Adachi H, Hakoshima M, |
| [15] |
Yanai H, Adachi H, Hakoshima M, |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
朱楠, 侯杰, 李洁, |
| [30] |
曾大勇, 王长连, 黄品芳, |
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
河北省卫健委、河北省红十字会 2026 年河北省医研企联合创新专项课题(LH20250020)
吴阶平医学基金会科研专项资助基金(320.6750.2025-18-14)
河北省医学适用技术跟踪项目(GZ2023035)
/
| 〈 |
|
〉 |